Download presentation
Presentation is loading. Please wait.
1
Immunotherapy for Lung Malignancies
Jonathan Chee, PhD, Bruce W.S. Robinson, MD, Robert A. Holt, PhD, Jenette Creaney, PhD CHEST Volume 151, Issue 4, Pages (April 2017) DOI: /j.chest Copyright © 2016 University of Western Australia Terms and Conditions
2
Figure 1 Tracking neoantigen-specific immune responses by enzyme-linked ImmunoSpot (ELISPOT). Representative picture of ELISPOT wells with spots that represent cells that produce interferon-γ in response to neoantigen peptide stimulation but not to the wild-type peptide sequence. Cells from tumor draining lymph nodes of five mice inoculated with the AB1-HA mesothelioma cell line were tested against predicted neoantigen-peptide-mutated Uqcrc2 (abbreviated to Uq2) and compared against wild-type Uqcrc2 peptide (left). Spots in each well are cells that respond to peptide stimulation. A dot plot quantifying the proportions of spot forming units in each well is shown on the right. MUT = mutant; WT = wild type. CHEST , DOI: ( /j.chest ) Copyright © 2016 University of Western Australia Terms and Conditions
3
Figure 2 Neoantigen immunotherapy in patients. Tumor samples from patients are sequenced for mutations and have their neoantigens predicted. Neoantigen peptides are synthesized for vaccination. Enzyme-linked ImmunoSpot (ELISPOT) and multimers are used to validate neoantigen T-cell responses in patients' blood. Once validated, T-cell responses in blood can be monitored longitudinally after different immunotherapies, vaccination, or chemotherapy and correlated with clinical outcomes. CHEST , DOI: ( /j.chest ) Copyright © 2016 University of Western Australia Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.